LY 3090106

Drug Profile

LY 3090106

Alternative Names: LY-3090106

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sjogren's syndrome
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 12 May 2016 Phase-I clinical trials in Sjogren's syndrome in Bulgaria & Romania (SC) (NCT02614716)
  • 01 Dec 2015 Phase-I clinical trials in Sjogren's syndrome in USA (SC) (NCT02614716)
  • 28 Nov 2015 Eli Lilly plans a phase I trial in Sjogren's syndrome in USA, Bulgaria, Georgia and Romania (SC) (NCT02614716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top